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The early glomerular changes in diabetes include a podocyte phenotype with loss of slit
diaphragm proteins, changes in the actin cytoskeleton and foot process architecture. This
review focuses on the role of the protein kinase C (PKC) family in podocytes and points
out the differential roles of classical, novel, and atypical PKCs in podocytes. Some PKC
isoforms are indispensable for proper glomerular development and slit diaphragm mainte-
nance, whereas others might be harmful when activated in the diabetic milieu. Therefore,
some might be interesting treatment targets in the early phase of diabetes.
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INTRODUCTION
Diabetic nephropathy (DN) is the most common cause of the end-
stage renal disease (ESRD) (1). The glomerular changes in DN are
characterized by excessive accumulation of extracellular matrix
(ECM) with thickening of glomerular and tubular basement
membranes and mesangial expansion, which ultimately progress
primarily to glomerulosclerosis and secondarily to tubulointersti-
tial fibrosis. The various cell types involved include glomerular
endothelial cells, mesangial cells, podocytes, and tubular epithelia,
which are all targets of hyperglycemic injury. However, accumulat-
ing evidence suggests that the extent of injury and loss of podocytes
is a major prognostic determinant in both, type I and type II DN
(2–6). As the terminally differentiated podocytes are believed to
play a critical role in maintaining the integrity of the glomerular
filtration barrier, effaced podocytes may contribute to the devel-
opment of albuminuria, a hallmark of DN. Although primarily
structure proteins were thought to be the key elements that com-
pose the slit diaphragm initially, it has become clear that the slit
diaphragm protein complex is a highly dynamic functional pro-
tein complex and is able to initiate cascades of signaling pathways
that affect podocyte function (7). More recent data indicate that
podocytes express receptors for many circulating hormones and
growth factors, which also suggest that a more complex cross-talk
between the kidney and other organs affected by diabetes may
occur in health and disease (8).
Among various signaling kinases, the protein kinase C (PKC)
family seems to play a critical role in the pathogenesis of DN (9).
The activation of PKCs in the kidney is a well-known pathway
of the diabetic milieu. The PKC family is involved in a variety
of signal transduction pathways, cell proliferation, differentiation,
cell cycle, and apoptosis. However, the role of PKCs on podocytes
in DN has not yet been fully defined. This present review will
give an overview of the general role of PKCs and summarize the
recent research into the regulatory role of PKCs in podocytes under
diabetic conditions.
PKC SUBFAMILIES AND ISOFORMS
All PKC isoforms contain a highly conserved catalytic domain
and a regulatory domain. The catalytic domain consists of
several motifs and is essential for the ATP/substrate-binding
and catalysis, whereas the N-terminal regulatory domain con-
tains an auto inhibitory pseudo-substrate domain and two dis-
crete membrane targeting modules, C1 and C2. The sequence
of pseudo-substrate contains an alanine in place of the ser-
ine/threonine phospho-acceptor site, but otherwise resembles a
PKC substrate (10).
Protein kinase C isoforms are subdivided into three subfam-
ilies based on differences of structure in their N-terminal regu-
latory domain. The isoforms α, βI, βII, and γ belong to conven-
tional PKCs (cPKCs). The regulatory domains of cPKCs contain
a C1 domain that functions as diacylglycerol (DAG)/phorbol
12-myristat 13-acetat (PMA) binding motif and a C2 domain
that binds anionic phospholipids in a calcium-dependent man-
ner (10). The novel PKCs (nPKCsδ, ε, η, and θ) also have two
C1 domains and a C2 domain. The nPKC C2 domains lack the
critical calcium-coordinating acidic residues, which is the distinct
difference between cPKC and nPKC. The nPKCs can be maxi-
mally activated by agonists that promote DAG accumulation or by
PMA, but they are insensitive to calcium. Atypical PKCs (aPKCs,
ζ, and λ/ι) lack a calcium-sensitive C2 domain; however, they con-
tain an atypical C1 domain, which binds PIP3 or ceramide, but
not DAG or PMA. The activity of aPKCs is primarily regulated
by protein–protein interaction and phosphorylation catalyzed by
phosphoinositide-dependent kinase-1 (PDK-1). Although a few
PKC isoforms are expressed in a tissue-specific manner, most are
ubiquitously expressed.
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REGULATION OF PKCs
Unless it is post-translationally or co-translationally phosphory-
lated, PKCs are incapable of being activated by DAG or other
cofactors (11, 12). PKC is translated as a catalytically inactive pro-
tein, is converted into an active enzyme by an initial phosphate
addition and then into a mature form by further phosphorylation
(11, 13, 14). In addition to phosphorylation on serine and thre-
onine residues, PKCs also undergo phosphorylation by tyrosine
kinases. PKCs are regulated by two sequential and equally critical
mechanisms: phosphorylation triggered by PDK-1 and binding
to DAG and/or other cofactors such as phosphatidylserine (PS)
or phorbol ester (PE). Each mechanism regulates the structure,
subcellular localization, and function of PKCs (15).
As a consequence of increased glycolytic flux, chronic hyper-
glycemia elevates the de novo synthesis of DAG and thus leads to an
increased activation of DAG dependent classic and novel PKC iso-
forms in cultured bovine aortic endothelial cells and smooth mus-
cle cells (16). Furthermore, high-glucose induced cellular levels
lead to an increased generation of advanced glycation end products
(AGEs), which initiate several signaling events by activating PKC,
MAP kinase, and transcription factors such as nuclear factor-κB
(NF-κB). This would increase the activity of various growth fac-
tors, such as TGF-β, and thereby alter expression of ECM proteins
(17). In addition, under high-glucose conditions PKC is activated
by higher concentrations of reactive oxygen species (ROS) gener-
ated following AGE:RAGE (AGE receptor) interactions (15, 18).
In turn, the ROS are generated via NADPH-oxidase activated by
PKC, ROS/PKC therefore can act in a cyclical manner to activate
one another (19).
CONVENTIONAL PKCs IN DIABETIC NEPHROPATHY
Among all the PKC isoforms, the role of PKCα in the pathogenesis
of DN has been investigated intensively, and several studies have
demonstrated that PKCα-deficient mice show a better outcome
after streptozotocin (STZ) induced diabetes with less proteinuria
and preserved nephrin expression (20, 21). Studies from our group
underline the involvement of PKCα in proteinuria development
in DN. The expression of PKCα in podocytes of patients with DN
was increased. Mice were treated after STZ-induced diabetes with
the synthetic PKCα inhibitor (GÖ6976), which prevented pro-
teinuria development and led to preserved nephrin expression.
Furthermore, we could show a central role for PKCα in endocy-
tosis of the slit diaphragm component nephrin (22, 23). Quack
et al. further concluded that proteinuria of diabetic mice is as a
result of increased endocytosis of nephrin, which is mediated by
a complex consisting of PKCα, protein interacting with c kinase-1
(PICK1), and beta-arrestin2. They found rising glucose levels go
along with increased binding of beta-arrestin to nephrin in vitro
as well as in in vivo, but only with preceding PKCα phosphory-
lating activity on nephrin. This fact and the indispensability of
PICK1 suggest PKCα and PICK1 as possible drug targets in early
stages of DN (23). These studies show that expression of PKCα
is regulated by glucose concentration in the external milieu of
the podocyte and that PKCα is directly involved in the mainte-
nance of the slit diaphragm. High levels of PKCα in podocytes
led to enhanced endocytosis of nephrin and instability of the slit
diaphragm.
In addition, Menne and colleagues demonstrated that the high-
glucose induced downregulation of nephrin is probably caused
by the PKCα mediated reduction of the transcriptional factor
Wilms tumor 1 (WT-1), which has previously been described as a
directly interacting binding partner of the nephrin promoter (24,
25). These findings are consistent with earlier studies, suggesting
one of the PKC isoforms might be pivotal for the regulation of
nephrin transcription and expression in podocytes (26), but not
for CD2AP and Podocin as they remain at levels similar to those
in non-diabetic kidneys (27).
Langham et al. showed that in diabetic patients treated with
perindopril, an ACE inhibitor, nephrin levels preserved resem-
bling those of non-diabetic subjects (28) and subsequently could
be one factor contributing to the anti-proteinuric effects of ACE
inhibitors. Another study suggests that the AGEs, which can be
inhibited by aminoguanidine, are also implicated in the downreg-
ulation of nephrin in diabetes (29). Interestingly, several groups
could demonstrate the reduction of PKC activity under the treat-
ment with ACE inhibitors and aminoguanidine in diabetic subjects
that could explain the nephrin protective effects (30, 31).
Most previous studies with specific PKCβ inhibitor ruboxistau-
rin (LX333531) in vivo and in vitro indicated that PKCβ isoform
is primarily responsible for the high-glucose-induced renal effects
in diabetes (32–36). Meier et al. tested this hypothesis by inducing
DN in PKCβ deficient mice and did not find a significant pre-
ventive effect of PKCβ deficiency on albuminuria. In contrast to
non-albuminuric diabetic PKCα−/− mice, the loss of the basement
membrane proteoglycan perlecan and the podocyte slit diaphragm
protein nephrin were not prevented in the PKCβ−/− mice under
diabetic conditions (20, 37). However, the hyperglycemia-induced
renal and glomerular hypertrophy as well as increased expression
of ECM proteins was reduced in PKCβ deficiency diabetic mice.
In summary, the two important physiological features of DN,
renal hypertrophy and albuminuria, are regulated through differ-
ent PKC isoforms; PKCα is involved in the development of albu-
minuria and maintenance the glomerular filtration barrier struc-
ture, whereas the PKCβ-isoform contributes to hyperglycemia-
induced renal fibrosis.
Another study by Menne et al. combined the findings about
PKCα and PKCβ and demonstrated that a dual inhibition of both
isoforms has a synergistic effect and is capable of preventing the
development of experimental DN in streptozocin-induced dia-
betic mice (38). Blocking both isoforms has a beneficial effect
on the development of renal hypertrophy and albuminuria in
mice after 8 weeks of diabetes. A pharmacological approach with
CGP41252, an inhibitor of PKCα and PKCβ showed that the
occurrence of albuminuria could be avoided and preexisting albu-
minuria could be diminished in both type I and type II diabetic
mice (38). But the treatment had little impact on the develop-
ment of renal hypertrophy. Higher doses treatment also increased
mortality.
ESSENTIAL ROLE OF NOVEL AND ATYPICAL PKCs
Only little is known about PKCε in renal function, especially about
its role in podocytes, although several previous studies showed
increased expression and activation of PKCε isoform in experi-
mental DN (39, 40). Meier et al. investigated the functional role of
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PKCε in renal physiology using PKCε-knockout mice and found
a renal phenotype with an elevated occurrence of tubulointersti-
tial fibrosis and glomerulosclerosis, whereas a systemic profibrotic
phenotype was not observed (41). Moreover, they demonstrated
an increased level of albuminuria in knockout mice whereas
the kidney/body ratio remained normal in comparison to non-
diabetic wild type mice, indicating that PKCε is probably less
implicated in development of renal hypertrophy. Experiments on
diabetic mice further showed that knockout of PKCε can exac-
erbate the renal phenotype with a significantly increased urinary
albumin/creatinine ratio and expression of ECM proteins. These
data suggest that a rising level of PKCε has a protective function
in kidney injury, rather than inducing profibrotic changes.
The atypical isoforms PKCλ and PKCι are both highly
expressed in podocytes. Although it is not clear whether both iso-
types perform distinct roles in the cell, aPKCs are well-known to
be important in the establishment of cell polarity (42, 43). They
form an evolutionarily conserved complex consisting of aPKC and
PAR3 and PAR6, two PDZ domain containing scaffold proteins
(44). Studies showed that the Par3–Par6–aPKC complex inter-
acts with nephrin–podocin through the direct connection of Par3
to nephrin, an essential structural component for the mainte-
nance of integrity of the glomerular filter as well as for the signal
transduction (45). Interestingly, our own studies of the glomeru-
lar development in regard to the Par polarity complex and slit
diaphragm molecules show that the PAR3–PAR6–aPKCλ com-
plex translocates together with other tight junction proteins like
ZO-1 from the apical to the basolateral side of the cell preceding
the targeting of slit diaphragm components such as nephrin and
podocin to the basal membrane, development of foot processes,
and the construction of slit diaphragms (46).
The very recent study of Satoh and colleagues shows the neces-
sity of aPKC in the exocytosis of newly produced nephrin and
its localization on the surface of podocytes (47). This finding
could also partially explain the diminished nephrin expression in
proteinuria patients with diabetes (48). Under high-glucose condi-
tions,activation of aPKC presents a protective effect on the nephrin
expression (48).
The activation of aPKC is required for the insulin-induced glu-
cose transport and thus defective aPKC activation in muscle and
adipocytes has been shown previously in type II diabetic rats, mon-
keys, and human beings, which leads to a disturbed glucose uptake
into muscle and the whole body glucose transfer (49). The knock-
out of the other isoform PKCζ has no specific renal phenotype
but seems to be able compensate for partial functions of aPKCλ
loss as the double-knockout leads to glomerular developmental
defects with no secondary foot processes (50). This is most likely
because of the regulatory cytoskeletal functions of aPKCs with
direct influence on small GTPase activation of aPKCs in podocytes
(51). Nevertheless, the role of aPKC in DN still remains unclear.
PKC UP-REGULATED GROWTH FACTOR EXPRESSION IN
DIABETIC NEPHROPATHY
Podocytes are the major site of vascular endothelial growth factor
(VEGF) production in the human kidney (52), and the expres-
sion of VEGF is increased in podocytes in diabetic rats and
human beings (53, 54). Thus, the up-regulation of VEGF plays
a critical role in the progression of DN. Hoshi et al. have shown
that under high-glucose conditions, VEGF expression was up-
regulated mediated through activation of PKC and extracellu-
lar signal-regulated kinase (ERK) in podocytes (55). PKC and
ERK are known to regulate activator protein-1 (AP-1) activation
(56–58), which promotes the binding of AP-1 to the promoter
region of the VEGF gene (59, 60). In addition, AGEs upregu-
late VEGF mRNA levels through transcription factors such as
NF-κB and AP-1. AGEs are also able to activate PKCs, which fur-
ther increase the expression of VEGF. Although VEGF is required
for normal glomerulogenesis and essential for maintenance of
glomerular filtration barrier, podocyte-specific overexpression of
VEGF164 or VEGF165 isoform in animals leads to structural and
functional renal changes similar to those abnormalities seen in
DN, including proteinuria, glomerular hypertrophy, glomeru-
lar basement membrane thickening, mesangial expansion, loss
of slit diaphragms, and podocyte effacement (61, 62). In DN,
the activation of TGF-β1 has been demonstrated to promote
podocyte apoptosis and the development of glomerulosclerosis.
A reduced expression level of the profibrotic cytokine TGF-β1
was detected in diabetic PKCβ−/− mice, while the alteration
was not observed in diabetic PKCα−/− mice (20). This obser-
vation suggested that PKCβ isoform is more important in the
up-regulation of TGF-β and for the development of glomeru-
lar fibrosis under diabetic conditions, whereas PKCα shows its
critical role in the integrity of glomerular filtration barrier (37).
However, PKCα plays a key role in the signaling response after
stimulation with TGF-β1. An enhanced and prolonged activation
of PI3K/AKT and ERK1/2 as well as a reduced proapoptotic signal-
ing via p38MAPK in PKCα-knockout podocytes compared to wild
type podocytes was detected after TGF-β1 treatment, which indi-
cated the involvement of PKCα in the TGF-β mediated apoptosis
(63).
Of note, deletion of PKCε signaling not only leads to increased
expression of TGF-β1 but also induces activation of the TGF-β1
signaling pathway in glomeruli (41). PKCι might also mediate a
high-glucose-induced increase in TGF-β receptor II (TGF-βRII)
promoter activity, which leads to the up-regulation of TGF-βRII
and fibronectin (64).
PKC REGULATED STRUCTURE PROTEINS IN PODOCYTES
P-cadherin as member of the classical cadherins, a superfamily of
glycoproteins, is known to be a basic scaffold for the glomerular
slit diaphragm (65). Xu et al. have first demonstrated decreased
expression of P-cadherin mRNA and protein in experimental dia-
betic glomeruli and in high-glucose stimulated podocytes, which
suggests that a potential role for P-cadherin loss in the devel-
opment of proteinuria in early DN (66). They also found that
PKC inhibitors could ameliorate the decrement of P-cadherin in
podocytes under high-glucose conditions. Thus, activation of PKC
regulated pathways seems to be involved in the regulation of P-
cadherin expression and contributes to the disruption of podocyte
integrity (66).
Nevertheless, it seems likely that the molecular changes of
the slit diaphragm complex, but not one single slit diaphragm-
associated molecule contribute to the pathogenesis of glomerular
filtration barrier in DN. P-cadherin, α-, β-, and γ-catenin, and
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FIGURE 1 | Schematic overview of PKC-isoform functions in
podocytes. DAG or calcium activated PKCα induces nephrin endocytosis
via the adaptor molecule Pick1. PKCλ/ι is required for foot process
formation, cell polarity, and nephrin exocytosis. PKCε might be involved in
actin remodeling via small GTPases and might orchestrate cell adhesion
and cell–cell contact formation.
ZO-1 are described to compose adherens junctions at the slit
diaphragm and establish the link with the actin cytoskeleton
(65, 67). However, the role and regulation of β-catenin with P-
cadherin and actin cytoskeletal proteins have not been thoroughly
explored. In the situation of the podocyte injury induced by high
glucose, β-catenin will be released from the destruction com-
plex because of the activation of the Wnt-pathway. Afterwards
β-catenin translocates into the nucleus to activate the down-
stream genes via the aggregation of a transcriptional complex with
TCF/LEF, which leads to proteinuria and glomerulosclerosis (68,
69). Several groups demonstrated that PKC activation phospho-
rylated N-terminal serine residues of β-catenin, which promoted
β-catenin degradation (70, 71). In contrast, our ongoing work
was focused on several PKC isoforms, whose activation is able
to dephosphorylate β-catenin to prevent β-catenin from degra-
dation. It is still unknown, whether this process is protective for
the high-glucose-induced cell adherens junction reduction. Nev-
ertheless, PKC activation may be a novel mechanism in regulating
β-catenin in glomerular injury, which will be further investigated
by our laboratory.
CONCLUSION
Podocyte injury or podocyte loss is a hallmark for the pathogene-
sis of DN. Based on the above described findings, PKC activation
seems to be the most critical pathway involved in the progression
of glomerular injury. Obviously, there is a fine balance between
activation and inactivation of the different PKC isoforms and
their cross-talk involving foot process cytoskeletal architecture,
cellular junction formation, and orchestration of turnover and
surface expression of slit diaphragm components (Figure 1).
Therefore, PKCs and their involved pathways are potential thera-
peutic targets in podocytes to prevent the progression of diabetic
glomerulopathy.
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